Drugs / buprenorphine-naloxone
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03291847 | Jun 2018 → Dec 2022 | neonatal abstinence syndrome | Johns Hopkins University | Completed | No outcome recorded |
| Phase 42 trials · 1 met primary | ||||||
| Phase 4 | NCT04283500 | Nov 2020 → Feb 2023 | opiate dependence | NYU Langone Health | Completed | No outcome recorded |
| Phase 4 | NCT03033732 | Oct 2017 → Mar 2020 | substance-related disorder | Didier Jutras Aswad | Completed | Met primary |
| Comparator or background therapy6 trials | ||||||
| Phase 2 | NCT03026790 Comparator | Oct 2017 → Mar 2022 | chronic pain syndrome | University of Minnesota | Completed | No outcome recorded |
| Phase 3 | NCT06023459 Comparator | Oct 2024 → Nov 2025 | substance-related disorder | Yih-Ing Hser | Completed | No outcome recorded |
| Phase 3 | NCT01131273 Comparator | Jun 2010 → Aug 2013 | HIV infectious disease | University of Pennsylvania | Completed | No outcome recorded |
| Phase 4 | NCT05450718 Comparator | Nov 2024 → Mar 2027 expected | substance-related disorder | Montefiore Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT05118204 Comparator | Sep 2022 → Oct 2024 | chronic pain syndrome, opiate dependence | Montefiore Medical Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02032433 Comparator | Jan 2014 → Jan 2017 | opiate dependence | NYU Langone Health | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Buprenorphine/Naloxone | “Buprenorphine/Naloxone is an opioid agonist treatment used to treat opioid use disorder.” NCT03033732 ↗9“Day 3: participants will receive buprenorphine-naloxone 2-0.5 mg every 8 hours” NCT05118204 ↗ |
| Known as | Suboxone | “buprenorphine-naloxone (Suboxone) for 12 weeks” NCT01131273 ↗ |
| Route | Oral | “Ingested orally via sublingual tablet form, flexible take home dosing.” NCT03033732 ↗ |